Navigation Links
Global Growth Factors (Blood And Tissue) Industry

nks Exclusive Global Licensing Agreement with Scil

Technology II-39

ZGEN Initiates Ph II Trial of Interleukin 21 II-39

FzioMed Bags Health Canada Approval on Oxiplex® II-40

NsGene A/S Implants Encapsulated Cell in Patients II-40

Reliance Life Sciences Takes Over Genemedix II-40

Fraunhofer Institute Introduces First Interferon Beta 1a to

Treat Multiple Sclerosis II-40

Shanghai Wanxing Inks Export Deal for Recombinant Human

Interferon II-41

Hemispherx Enters into Distribution Agreement with Armada II-41

Bayer Establishes US Pharmaceuticals Subsidiary II-41

Merck Inks Agreement with Bristol-Myers Squibb and ImClone II-41

CoGenesys Signs Global Licensing Agreement with Vegenics II-42

InterMune Inks New Supply Deal with Boehringer Ingelheim II-42

Boston Life Sciences Adopts New Name of Alseres Pharmaceuticals II-42

Cambrex Divests Bioproducts and Biopharma Subsidiaries II-43

Dragon Divests EPO Business II-43

Caregene and Genzyme Forms Partnership to Develop Cere-120 II-43

NsGene to Undertake Phase Ib Clinical Trial of NsG0202 II-44

Roche Receives European approval for NeoRecormon II-44

Bolder Receives Two U.S. Patents for Hematopoietic Factors II-44

RLS to Initiate Clinical Trials of Erythropoietin II-44

InterMune Drops Phase III trial of Interferon II-44

Chugai to Conduct Additional Trial on Epogin® II-45

Merck KGaA Acquires Serono Labs II-45

CytoPharm Acquires Low-Dose Interferon License from Amarillo

Biosciences II-45

Hospira Signs Agreements with STADA and BIOCEUTICALS for

Erythropoietin II-45

Biocon Bags GEAC Approval to Conduct Clinical Trial of

Granulocyte Colony Stimulating Factor II-46

SII to Conduct Clinical Trials of Rdna Products II-46

Claris to Construct Production Facility for EOP II-46

Mayne and Pliva to End Coll

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Global Angiogenesis Inhibitors and Stimulators Industry
2. MarketsandMarkets: Global Healthcare Cloud Computing Market Worth $5,419.8 Million by 2017
3. Global Electrodes for Medical Devices Industry
4. NeuroSigma Receives Global Quality Control Certification
5. MarketsandMarkets: Global Radiotherapy Devices Market Worth $5.8 Billion by 2016
6. Demand for Product Pipeline Review and Analysis Rises in the Global Pharma Industry
7. 3SBio Obtains SFDA Approval to Join Global Phase III Trial for Voclosporin
8. Global Drug-Eluting Stents Industry
9. Global Pain Management Industry
10. Pharmaceuticals: Global Industry Almanac, MarketLine
11. Global Information, Inc. Announces New Market Forecasts For Drug Discovery Industry as it Emerges from Recession
Post Your Comments:
(Date:7/29/2014)... SAN DIEGO , July 29, 2014  Neurocrine ... that the Company will report its second quarter 2014 ... August 6, 2014.  Neurocrine will then host a live ... and provide a Company update Thursday morning, August 7, ... Time). Participants can access the live conference ...
(Date:7/29/2014)... TORONTO , July 29, ... ESAQ), an emerging pharmaceutical company exploring drug ... novel formulations and alternative dosage forms of ... its pharmaceutical development implementing its sub-micron platform technology.  ... drugs that will address indications in diabetes ...
(Date:7/29/2014)... LINCOLNSHIRE, Ill. , July 29, 2014  Sysmex ... equipment and information systems technology, will feature an exhibit ... (AACC) Annual Meeting and Clinical Lab Expo in ... 31, 2014. "We are extremely excited ... tremendous opportunity to interact with our customers and continue ...
Breaking Medicine Technology:Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3
(Date:7/29/2014)... The Board of Governors of the State Bar ... Connie Akridge to serve as a trustee of ... the Foundation. Akridge served as President of the State Bar ... Holland & Hart in Las Vegas, providing tailored counsel on ... and healthcare clients for more than 25 years. She regularly ...
(Date:7/29/2014)... New high priced hepatitis C drugs ... a projected $2.9 to $5.8 billion next year, according ... released today by the Pharmaceutical Care Management Association (PCMA). ... by as much as 8.6 percent in 2015 as ... and Olysio. , The study finds that the majority ...
(Date:7/29/2014)... The Law Offices of Michael Cordova is ... a non-profit organization providing grief camps for kids, teens, adults, ... suffering our clients experience from the death of a loved ... organization like Stepping Stones of Hope, as they provide hope ... of Hope also includes a monthly support group and a ...
(Date:7/29/2014)... app that helps headache sufferers to record the severity ... part of a Griffith research study. , A new ... looks at coping with their triggers and is being ... Behaviorial Basis of Health program. , He has developed ... the triggers of their headaches called Learning to Cope ...
(Date:7/29/2014)... most cases of cancer is to surgically remove the ... that the surgeon may fail to extract the entire ... new technique, researchers at the University of Pennsylvania have ... entire tumor in the patient, increasing the likelihood of ... dye that accumulates in cancerous tissues much more so ...
Breaking Medicine News(10 mins):Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:The Law Offices of Michael Cordova is Sponsoring Stepping Stones of Hope, a Non-Profit Organization Providing Grief Camps for Kids, Teens, Adults, and Families 2Health News:Penn team makes cancer glow to improve surgical outcomes 2Health News:Penn team makes cancer glow to improve surgical outcomes 3
... risk of dementia according to recent research. // ,People ... risk of dementia and Alzheimer’s disease. ,DHA or docosahexaenoic ... that is required for the proper functioning of the central ... issue of the Archives or Neurology. ,According to lead ...
... An Austrian study points out that the risk of developing ... results of the study done by researchers from Medical University ... ,The study found out that marathon runners have increased chances ... .Both liver spots and moles reflect a higher risk to ...
... virus boost the cancer-killing abilities of existing cancer drugs? ... on Molecular Targets and Cancer Therapeutics, in Prague, Czech ... may lead to more effective treatment options for patients ... in which malignant (cancer) cells form in the tissues ...
... law to register all health care infrastructure in the country ... // ,"The act named as the Clinical Establishment Act ... and will register all health care institutes, infrastructure and human ... in a function entitled "Public Health Initiative: PPP model"., ...
... Hobart Hospital who are attending to babies born to ... the babies are discharged from the hospital. It is ... addictions at the hospital annually., ,The director ... Peter Dargaville, said, "We see the most severely affected ...
... that more than two thirds of the Britons fearing heart ... an ambulance. //The reluctance in calling emergency help have proved ... to be the biggest killer, often killing at least one ... ,The poll was conducted under the BHF's 'Doubt Kills' ...
Cached Medicine News:Health News:Common Virus Enhances Cancer-Fighting Ability of Standard Chemotherapy Drugs 2
... Sodium Hyaluronate (1.8%) viscoelastic solution combines maximum ... Rayflo maintains a deep anterior chamber and ... is ideal for routine cataract surgery but ... requiring a viscoelastic. Combine all these properties ...
... Healon5 is a sterile, non-pyrogenic, transparent ... noninflammatory, high molecular weight (average molecular ... Healon5 contains 23 mg/mL of sodium ... units of N-acetylglucosamine and sodium glucuronate ...
... is a highly retentive, dispersive viscoelastic. ... weight, low pseudoplasticity and low surface ... and excellent tissue protection. It is ... (catalog number 8065183905) or as part ...
... planning workstation is used to plan precisely ... Planning Workstation, the surgeon can simulate the ... the patient. This enables the selection of ... material waste and procedural costs. The surgeon ...
Medicine Products: